- < General Internal Medicine
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
By sjmartinez • January 23, 2025
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. Epub ahead of print. PMID: 39843940.
Related Posts
Wisk LE, Leifheit KM. Important Role of Social Policies to Prevent Child Maltreatment. JAMA Pediatr. 2026 Jan 26. doi: 10.1001/jamapediatrics.2025.5964. Epub ahead of print. PMID:[...]
Guan M, Chang L. Biomarkers in Irritable Bowel Syndrome: Rationale and Practical Use. Gastroenterol Clin North Am. 2026 Mar;55(1):91-105. doi: 10.1016/j.gtc.2025.08.002. Epub 2025 Oct 21.[...]
Johnson SA, Klimis-Zacas D, Basu A, Bolling BW, Feresin RG, Hooshmand S, Joris PJ, Li Z, Lila MA, Stull AJ, Anandh Babu PV, Weir TL.[...]
